Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
No. of COVID-19 Cases Hikes, Triggering Speculation in Related Pharma; CSPC PHARMA/ JUNSHI BIO/ SIMCERE PHARMA/ BRII-B Surge 10%+
Recommend 26 Positive 33 Negative 10 |
||||
|
||||
|
Some countries and regions in Asia recently saw an increase in the number of COVID-19 cases. According to Nikkei Asia, hundreds of thousands of COVID-19 cases have been reported in countries including China and Singapore, killing at least 46 people in Thailand alone. An Zhijie, a researcher at the Chinese Center for Disease Control and Prevention (CCDC), said at a press conference on 20 May that there had been an increase in the number of COVID-19 cases in some countries and regions, but there had been no significant change in the severity of the disease. COVID-19-related pharma were speculated today (29th). JUNSHI BIO (01877.HK) rose to $21.35, setting nearly-8-month high, and last soared 15.51% to $21, with a turnover of $329 million. SIMCERE PHARMA (02096.HK) peaked at $12.72, an over-2-year high, and spiked 13% to last at $12.34, with a turnover of $361 million. Other COVID-19 concept stocks followed the uptrend. FOSUN PHARMA (02196.HK) elevated 4.2%, while CANSINOBIO (06185.HK) and XTALPI (02228.HK) mushroomed 6.2-7%. CSPC PHARMA (01093.HK), which announced its 1Q results at noon today (29th), and BRII-B (02137.HK) even surged over 10%. AAStocks Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
